AvenCell Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Medical
AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies. Their proprietary Universal Switchable CAR-T cell therapy platform is designed to treat various hematologic malignancies and autoimmune diseases. AvenCell aims to transform the standard of care with innovative and adaptable cell therapy t
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 63
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- avencell.com
- Company page
Recent activity at AvenCell Therapeutics
- : AvenCell Therapeutics secures $47M from Ligand Pharmaceuticals for Series C financing and CAR-T drug development, with funding tied to clinical milestones.
- : AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.
AvenCell Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Series C | $47.0M |
| Oct 2024 | Series B | $112.0M |
Leadership
- Babar Ghias, Chief Financial Officer
- Andrew Schiermeier, Chief Executive Officer
- Jan Pape, Head of Finance Eu / Prokurist
- Andrea Kistner, VP of Finance and Corporate Controller
Verified email and direct lines for AvenCell Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
AvenCell Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
AvenCell Therapeutics in the news
- Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million - Yahoo Finance (Sep 24, 2026)
- AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026 - BioSpace (Jun 03, 2026)
- AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies - PR Newswire (Apr 02, 2026)
- AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinic - Fierce Biotech (Oct 22, 2024)
- Novo Holdings leads $112M investment in Watertown biotech - The Business Journals (Oct 22, 2024)
- Novo Holdings Leads AvenCell’s $112 Million Series B Financing to Advance Next-Generation Cell Therapy Treatments - Novo Holdings (Oct 22, 2024)
- European Clinical Trial Approved for First CRISPR-Engineered Switchable Allogeneic CAR-T Candidate - CRISPR Medicine News (Aug 09, 2023)
- Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance (Sep 27, 2026)
Companies similar to AvenCell Therapeutics
- Novadip Biosciences · Biotechnology, Health Care, Medical, Therapeutics
- Abivax · Biotechnology, Health Care, Medical, Therapeutics
- N-Power Medicine · Biotechnology, Health Care, Medical, Therapeutics
- ALX Oncology · Biotechnology, Health Care, Medical, Therapeutics
- Scipher Medicine · Biotechnology, Health Care, Medical, Therapeutics
About AvenCell Therapeutics: questions and answers
What does AvenCell Therapeutics do?
AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies. Their proprietary Universal Switchable CAR-T cell therapy platform is designed to treat various hematologic malignancies and autoimmune diseases. AvenCell aims to transform the standard of care with innovative and adaptable cell therapy t
Where is AvenCell Therapeutics headquartered?
AvenCell Therapeutics is headquartered in Cambridge, Massachusetts, United States.
How many employees does AvenCell Therapeutics have?
AvenCell Therapeutics has about 63 employees.
Has AvenCell Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for AvenCell Therapeutics. The most recent, Series C of $47.0M, was in Sep 2026.
Who leads AvenCell Therapeutics?
Andrew Schiermeier is a Chief Executive Officer at AvenCell Therapeutics.
What is the latest news on AvenCell Therapeutics?
On Sep 27, 2026, AvenCell Therapeutics secures $47M from Ligand Pharmaceuticals for Series C financing and CAR-T drug development, with funding tied to clinical milestones.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy